|
1
|
Schultz DC, Vanderveer L, Berman DB,
Hamilton TC, Wong AJ and Godwin AK: Identification of two candidate
tumor suppressor genes on chromosome 17p13.3. Cancer Res.
56:1997–2002. 1996.PubMed/NCBI
|
|
2
|
Phillips N, Ziegler M, Saha B and Xynos F:
Allelic loss on chromosome 17 in human ovarian cancer. Int J
Cancer. 54:85–91. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Phillips NJ, Ziegler MR, Radford DM, Fair
KL, Steinbrueck T, Xynos FP and Donis-Keller H: Allelic deletion on
chromosome 17p13.3 in early ovarian cancer. Cancer Res. 56:606–611.
1996.PubMed/NCBI
|
|
4
|
Bruening W, Prowse AH, Schultz DC,
Holgado-Madruga M, Wong A and Godwin AK: Expression of OVCA1, a
candidate tumor suppressor, is reduced in tumors and inhibits
growth of ovarian cancer cells. Cancer Res. 59:4973–4983.
1999.PubMed/NCBI
|
|
5
|
Li AJ and Karlan BY: Genetic factors in
ovarian carcinoma. Curr Oncol Rep. 3:27–32. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Phillips NJ, Zeigler MR and Deaven LL: A
cDNA from the ovarian cancer critical region of deletion on
chromosome 17p13.3. Cancer Lett. 102:85–90. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schultz DC, Balasara BR, Testa JR and
Godwin AK: Cloning and localization of a human diphthamide
biosynthesis-like protein-2 gene, DPH2L2. Genomics. 52:186–191.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu S, Milne GT, Kuremsky JG, Fink GR and
Leppla SH: Identification of the proteins required for biosynthesis
of diphthamide, the target of bacterial ADP-ribosylating toxins on
translation elongation factor 2. Mol Cell Biol. 24:9487–9497. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mayer K, Schröder A, Schnitger J, Stahl S
and Brinkmann U: Influence of DPH1 and DPH5 protein variants on the
synthesis of diphthamide, the target of ADPRibosylating toxins.
Toxins (Basel). 9:E782017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stahl S, da Silva Mateus Seidl AR, Ducret
A, Kux van Geijtenbeek S, Michel S, Racek T, Birzele F, Haas AK,
Rueger R, Gerg M, et al: Loss of diphthamide pre-activates NF-κB
and death receptor pathways and renders MCF7 cells hypersensitive
to tumor necrosis factor. Proc Natl Acad Sci USA. 112:10732–10737.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Webb TR, Cross SH, McKie L, Edgar R, Vizor
L, Harrison J, Peters J and Jackson IJ: Diphthamide modification of
eEF2 requires a J-domain protein and is essential for normal
development. J Cell Sci. 121:3140–3145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nobukuni Y, Kohno K and Miyagawa K: Gene
trap mutagenesis-based forward genetic approach reveals that the
tumor suppressor OVCA1 is a component of the biosynthetic pathway
of diphthamide on elongation factor 2. J Biol Chem.
280:10572–10577. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen CM and Behringer RR: Cloning,
structure, and expression of the mouse Ovca1 gene. Biochem Biophys
Res Commun. 286:1019–1026. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen CM and Behringer RR: Ovca1 regulates
cell proliferation, embryonic development, and tumorigenesis. Genes
Dev. 18:320–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jensen MR and Helin K: OVCA1: Emerging as
a bona fide tumor suppressor. Genes Dev. 18:245–248. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
L'Allemain G: Ovca1 gene, deleted in
ovarian cancer is a special tumor suppressor. Bull Cancer.
91:301–302. 2004.(In French). PubMed/NCBI
|
|
17
|
Chen CM and Behringer RR: OVCA1: Tumor
suppressor gene. Curr Opin Genet Dev. 15:49–54. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liang M, Ayanga B, Du S, Godwin AK,
Hartsock JK and Evans SC: Ovca1, a candidate gene of the genetic
modifier of Tp53, Mop2, affects mouse embryonic lethality. Genes
Chromosomes Cancer. 47:315–325. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kong F, Tong R, Jia L, Wei W, Miao X, Zhao
X, Sun W, Yang G and Zhao C: OVCA1 inhibits the proliferation of
epithelial ovarian cancer cells by decreasing cyclin D1 and
increasing p16. Mol Cell Biochem. 354:199–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu YR, You LR, Yan YT and Chen CM: Role of
OVCA1/DPH1 in craniofacial abnormalities of Miller-Dieker syndrome.
Hum Mol Genet. 23:5579–5596. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wiper DW, Zanotti KM, Kennedy AW, Belinson
JL and Casey G: Analysis of allelic imbalance on chromosome 17p13
in stage I and stage II epithelial ovarian cancers. Gynecol Oncol.
71:77–82. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Prowse AH, Vanderveer L, Milling SW, Pan
ZZ, Dunbrack RL, Xu XX and Godwin AK: OVCA2 is downregulated and
degraded during retinoid-induced apoptosis. Int J Cancer.
99:185–192. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rock KL, Gramm C, Rothstein L, Clark K,
Stein R, Dick L, Hwang D and Goldberg AL: Inhibitors of the
proteasome block the degradation of most cell-proteins and the
generation of peptides presented on MHC class-I molecules. Cell.
78:761–771. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jullig M, Zhang WV, Ferreira A and Stott
NS: MG132 induced apoptosis is associated with p53-independent
induction of pro-apoptotic Noxa and transcriptional activity of
beta-catenin. Apoptosis. 11:627–641. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han YH, Moon HJ, You BR and Park WH: The
effect of MG132, a proteasome inhibitor on HeLa cells in relation
to cell growth, reactive oxygen species and GSH. Oncol Rep.
22:215–221. 2009.PubMed/NCBI
|
|
26
|
Han YH and Park WH: MG132 as a proteasome
inhibitor induces cell growth inhibition and cell death in A549
lung cancer cells via influencing reactive oxygen species and GSH
level. Hum Exp Toxicol. 29:607–614. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo N and Peng Z: MG132, a proteasome
inhibitor, induces apoptosis in tumor cells. Asia Pac J Clin Oncol.
9:6–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gong Y, Wang D, Dar JA, Singh P, Graham L,
Liu W, Ai J, Xin Z, Guo Y and Wang Z: Nuclear export signal of
androgen receptor (NESAR) regulation of androgen receptor level in
human prostate cell lines via ubiquitination and
proteasome-dependent degradation. Endocrinology. 153:5716–5725.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Watanabe-Asano T, Kuma A and Mizushima N:
Cycloheximide inhibits starvation-induced autophagy through mTORC1
activation. Biochem Biophys Res Commun. 445:334–339. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fu C, Chen D, Chen R, Hu Q and Wang G: The
schizophrenia-related protein dysbindin-1A is degraded and
facilitates NF-Kappa B activity in the nucleus. PLoS One.
10:e01326392015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakagawa K and Yokosawa H: Degradation of
transcription factor IRF-1 by the ubiquitin-proteasome pathway. The
C-terminal region governs the protein stability. Eur J Biochem.
267:1680–1686. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lecker SH, Goldberg AL and Mitch WE:
Protein degradation by the ubiquitin-proteasome pathway in normal
and disease states. J Am Soc Nephrol. 17:1807–1819. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Knecht E, Aguado C, Cárcel J, Esteban I,
Esteve JM, Ghislat G, Moruno JF, Vidal JM and Sáez R: Intracellular
protein degradation in mammalian cells: Recent developments. Cell
Mol Life Sci. 66:2427–2443. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Groll M, Ditzel L, Löwe J, Stock D,
Bochtler M, Bartunik HD and Huber R: Structure of 20S proteasome
from yeast at 2.4 A resolution. Nature. 386:463–471. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Doherty FJ, Dawson S and Mayer RJ: The
ubiquitin-proteasome pathway of intracellular proteolysis. Essays
Biochem. 38:51–63. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fuchs SY: The role of ubiquitin-proteasome
pathway in oncogenic signaling. Cancer Biol Ther. 1:337–341. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schmidt M and Finley D: Regulation of
proteasome activity in health and disease. Biochim Biophys Acta.
1843:13–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu J, Shaik S, Dai X, Wu Q, Zhou X, Wang
Z and Wei W: Targeting the ubiquitin pathway for cancer treatment.
Biochim Biophys Acta. 1855:50–60. 2015.PubMed/NCBI
|
|
39
|
D'Arcy P and Linder S: Proteasome
deubiquitinases as novel targets for cancer therapy. Int J Biochem
Cell Biol. 44:1729–1738. 2012. View Article : Google Scholar : PubMed/NCBI
|
